IRF4 haploinsufficiency in a family with Whipple's disease
Abstract
Most humans are exposed to Tropheryma whipplei (Tw). Whipple's disease (WD) strikes only a small minority of individuals infected with Tw (<0.01%), whereas asymptomatic chronic carriage is more common (<25%). We studied a multiplex kindred, containing four WD patients and five healthy Tw chronic carriers. We hypothesized that WD displays autosomal dominant (AD) inheritance, with age-dependent incomplete penetrance. We identified a single very rare non-synonymous mutation in the four patients: the private R98W variant of IRF4, a transcription factor involved in immunity. The five Tw carriers were younger, and also heterozygous for R98W. We found that R98W was loss-of-function, modified the transcriptome of heterozygous leukocytes following Tw stimulation, and was not dominant-negative. We also found that only six of the other 153 known non-synonymous IRF4 variants were loss-of-function. Finally, we found that IRF4 had evolved under purifying selection. AD IRF4 deficiency can underlie WD by haploinsufficiency, with age-dependent incomplete penetrance.
Data availability
-
IRF4 haplo-insufficiency underlies a familial form of Whipple's diseasePublicly available at the NCBI Gene Expression Omnibus (accession no: GSE102862).
Article and author information
Author details
Funding
Centre National de la Recherche Scientifique
- Lluis Quintana-Murci
Agence Nationale de la Recherche (ANR-14-CE14-0008-02)
- Lluis Quintana-Murci
Agence Nationale de la Recherche (ANR-14-CE14-0007-02)
- Lluis Quintana-Murci
H2020 European Research Council
- Lluis Quintana-Murci
National Health and Medical Research Council (1113904)
- Stuart G Tangye
University of New South Wales
- Lisa Worley
- Tina Nguyen
Agence Nationale de la Recherche (ANR-16-CE17-0005-01)
- Antoine Guérin
National Institutes of Health (5R01AI089970-02)
- Jean-Laurent Casanova
National Health and Medical Research Council (1042925)
- Cindy S Ma
Office of Health and Medical Research
- Cindy S Ma
- Stuart G Tangye
H2020 European Research Council (281297)
- Lluis Quintana-Murci
- Jean-Laurent Casanova
Seventh Framework Programme (FP/2007-2013)
- Lluis Quintana-Murci
Agence Nationale de la Recherche (ANR-IFNPHOX (ANR-13-ISV3-001-01))
- Jacinta Bustamante
Agence Nationale de la Recherche (ANR-10-LABX-62-IBEID)
- Lluis Quintana-Murci
- Laurent Abel
- Jean-Laurent Casanova
Agence Nationale de la Recherche (ANR-GENMSMD (ANR-16-CE17-0005-01))
- Jacinta Bustamante
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Jos WM van der Meer, Radboud University Medical Centre, Netherlands
Ethics
Human subjects: Informed consent was obtained from all family members, and the study was approved by the national ethics committee.
Version history
- Received: September 28, 2017
- Accepted: March 12, 2018
- Accepted Manuscript published: March 14, 2018 (version 1)
- Version of Record published: April 24, 2018 (version 2)
Copyright
© 2018, Guérin et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,891
- views
-
- 501
- downloads
-
- 46
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Immunology and Inflammation
We studied lysosomal Ca2+ in inflammasome. Lipopolysaccharide (LPS) + palmitic acid (PA) decreased lysosomal Ca2+ ([Ca2+]Lys) and increased [Ca2+]i through mitochondrial ROS, which was suppressed in Trpm2-KO macrophages. Inflammasome activation and metabolic inflammation in adipose tissue of high-fat diet (HFD)-fed mice were ameliorated by Trpm2 KO. ER→lysosome Ca2+ refilling occurred after lysosomal Ca2+ release whose blockade attenuated LPS + PA-induced inflammasome. Subsequently, store-operated Ca2+entry (SOCE) was activated whose inhibition suppressed inflammasome. SOCE was coupled with K+ efflux whose inhibition reduced ER Ca2+ content ([Ca2+]ER) and impaired [Ca2+]Lys recovery. LPS + PA activated KCa3.1 channel, a Ca2+-activated K+ channel. Inhibitors of KCa3.1 channel or Kcnn4 KO reduced [Ca2+]ER, attenuated increase of [Ca2+]i or inflammasome activation by LPS + PA, and ameliorated HFD-induced inflammasome or metabolic inflammation. Lysosomal Ca2+ release induced delayed JNK and ASC phosphorylation through CAMKII-ASK1. These results suggest a novel role of lysosomal Ca2+ release sustained by ER→lysosome Ca2+ refilling and K+ efflux through KCa3.1 channel in inflammasome activation and metabolic inflammation.
-
- Immunology and Inflammation
The autoimmune disease lupus erythematosus (lupus) is characterized by photosensitivity, where even ambient ultraviolet radiation (UVR) exposure can lead to development of inflammatory skin lesions. We have previously shown that Langerhans cells (LCs) limit keratinocyte apoptosis and photosensitivity via a disintegrin and metalloprotease 17 (ADAM17)-mediated release of epidermal growth factor receptor (EGFR) ligands and that LC ADAM17 sheddase activity is reduced in lupus. Here, we sought to understand how the lupus skin environment contributes to LC ADAM17 dysfunction and, in the process, differentiate between effects on LC ADAM17 sheddase function, LC ADAM17 expression, and LC numbers. We show through transcriptomic analysis a shared IFN-rich environment in non-lesional skin across human lupus and three murine models: MRL/lpr, B6.Sle1yaa, and imiquimod (IMQ) mice. IFN-I inhibits LC ADAM17 sheddase activity in murine and human LCs, and IFNAR blockade in lupus model mice restores LC ADAM17 sheddase activity, all without consistent effects on LC ADAM17 protein expression or LC numbers. Anti-IFNAR-mediated LC ADAM17 sheddase function restoration is associated with reduced photosensitive responses that are dependent on EGFR signaling and LC ADAM17. Reactive oxygen species (ROS) is a known mediator of ADAM17 activity; we show that UVR-induced LC ROS production is reduced in lupus model mice, restored by anti-IFNAR, and is cytoplasmic in origin. Our findings suggest that IFN-I promotes photosensitivity at least in part by inhibiting UVR-induced LC ADAM17 sheddase function and raise the possibility that anifrolumab ameliorates lupus skin disease in part by restoring this function. This work provides insight into IFN-I-mediated disease mechanisms, LC regulation, and a potential mechanism of action for anifrolumab in lupus.